Blueprint Medicines (FRA:2L9) Marketable Securities : €491.8 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Blueprint Medicines's Marketable Securities for the quarter that ended in Mar. 2024 was €491.8 Mil.

Blueprint Medicines's annual Marketable Securities increased from Dec. 2021 (€236.4 Mil) to Dec. 2022 (€779.1 Mil) but then declined from Dec. 2022 (€779.1 Mil) to Dec. 2023 (€586.3 Mil).

Blueprint Medicines Marketable Securities Historical Data

The historical data trend for Blueprint Medicines's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Marketable Securities Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

332.65

153.89

236.44

779.07

586.29

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															609.38	597.28	615.62	586.29	491.81

Blueprint Medicines Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Blueprint Medicines (FRA:2L9) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Blueprint Medicines Marketable Securities Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (FRA:2L9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

BPMC:USA 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (FRA:2L9) Headlines

No Headlines